Last reviewed · How we verify
Toragesic®
Toragesic is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis.
Toragesic is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting prostaglandin synthesis. Used for Relief of moderate to severe pain.
At a glance
| Generic name | Toragesic® |
|---|---|
| Sponsor | Apsen Farmaceutica S.A. |
| Drug class | NSAID |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
This inhibition of prostaglandin synthesis leads to a reduction in inflammation and pain. Toragesic is a selective COX-2 inhibitor, which means it preferentially targets the COX-2 enzyme over COX-1, reducing gastrointestinal side effects.
Approved indications
- Relief of moderate to severe pain
Common side effects
- Gastrointestinal upset
- Dizziness
- Headache
Key clinical trials
- Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction (PHASE3)
- The Effect of Different Drugs in the Prevention of Tooth Sensitivity Caused by Tooth Bleaching Treatment. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Toragesic® CI brief — competitive landscape report
- Toragesic® updates RSS · CI watch RSS
- Apsen Farmaceutica S.A. portfolio CI